Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling

21 Nov 2022

Abstract excerpt

Abiraterone is a standard treatment for metastatic castrate-resistant prostate cancer (mCRPC) that slows disease progression by abrogating androgen synthesis and antagonizing the androgen receptor (AR). Here we report that inhibitors of the mitotic regulator polo-like kinase-1 (Plk1), including the clinically active third-generation Plk1 inhibitor onvansertib, synergizes with abiraterone in vitro and in vivo to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Microtubule and mitosis dynamics
Share to Neuroblastoma Research and Treatments
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36413141
DOI: 10.1158/0008-5472.can-22-1533

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor SignalingPMID 36413141Read ↗

Polo-like kinase-1 Inhibitors and the Antiandrogen Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor SignalingSemantic proximity Read ↗

Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of Polo-like kinase 1 and microtubule dynamicsSemantic proximity Read ↗

Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in OncologySemantic proximity Read ↗

Mitotic Poisons In Cancer PharmacotherapySemantic proximity Read ↗

Mitotic kinases are emerging therapeutic targets against metastatic breast cancerSemantic proximity Read ↗

A review of Plks: Thinking outside the (polo) boxSemantic proximity Read ↗

Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agentsSemantic proximity Read ↗

Plk1 Inhibition Causes Post-Mitotic DNA Damage and Senescence in a Range of Human Tumor Cell LinesSemantic proximity Read ↗

Maximizing Anticancer Response with MPS1 and CENPE Inhibition Alongside Apoptosis InductionSemantic proximity Read ↗

Mitotic Poisons in Research and MedicineSemantic proximity Read ↗

How do anti-mitotic drugs kill cancer cells?Semantic proximity Read ↗

The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.